Eisai initiates two phase III studies of Fycompa (perampanel) for Lennox-Gastaut syndrome.

Eisai Inc. announced the initiation of two multi-center, global Phase III clinical trials assessing Fycompa (perampanel) CIII in two different patient populations: patients age 2 years and above with inadequately controlled seizures associated with Lennox-Gastaut Syndrome (LGS) (Study 338), a rare and often debilitating form of childhood-onset epilepsy, and in children ages 4 through 11 years with inadequately controlled partial-onset seizures (POS) (Study 311).